Reviva Pharmaceuticals Holdings Inc.

-0.01 (-0.56%)
Products, Regulatory

Reviva Pharmaceuticals Announces Update On Recover, A Pivotal Phase 3 Global Study Evaluating Brilaroxazine For Treatment Of Schizophrenia

Published: 05/03/2022 11:45 GMT
Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals Announces Update on Recover, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for Treatment of Schizophrenia.
Reviva Pharmaceuticals Holdings, Inc. - Announced That Recover Study is Progressing Well and All Sites in United States (u.s.) Have Been Initiated.
Reviva Pharmaceuticals Holdings, Inc. - Global Sites in Europe and India Remain on Track to Initiate in Mid-2022.
Reviva Pharmaceuticals- Phase 3 Recover Study Continues to Progress Well, With Brilaroxazine Demonstrating Safe and Well Tolerated Profile.
Reviva Pharmaceuticals- Look Forward to Sharing Further Updates on Enrollment in Second Half of 2022 & Anticipate Providing Topline Data in Mid-2023.